secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001104659-24-103942
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics completes enrollment of 188 patients in Phase 2 DeFianCe study of DKN-01 for CRC
--------------------------------------------------------------------------------

- Enrolled 188 patients in randomized controlled Part B of DeFianCe study (NCT05480306).
- Evaluates DKN-01 + bevacizumab + chemo as second-line therapy for advanced colorectal cancer.
- Primary endpoint: progression-free survival overall and in left-sided CRC subpopulation.
- Initial data from Part B expected in mid-2025; Part A showed encouraging response rates.
- Study expanded from 130 to 188 patients, reflecting investigator and patient interest.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924103942/0001104659-24-103942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465924103942/tm2425162d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-103942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer